Primary intrathoracic dermatofibrosarcoma protuberans

American Journal of Surgical Pathology

Volumn 36, Issue 12, 2012, Pages 1897-1902

  King, Lauren ^a   López Terrada, Dolores ^b   Jakacky, Jared ^b   McCarville, M Beth ^a   Spunt, Sheri L ^a   Bridge, Julia A ^c   Bahrami, Armita ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b TEXAS CHILDREN S HOSPITAL   (United States)

^c NEBRASKA MEDICAL CENTER   (United States)

Author keywords

COL1A1; dermatofibrosarcoma protuberans; fibrosarcoma; fluorescence in situ hybridization; molecular genetics; PDGFB

Indexed keywords

CD34 ANTIGEN; COLIA1 PDGFB FUSION PROTEIN, HUMAN; COLIA1-PDGFB FUSION PROTEIN, HUMAN; ONCOPROTEIN; TUMOR MARKER;

ARTICLE; CASE REPORT; CHEMISTRY; CHILD; DERMATOFIBROSARCOMA PROTUBERANS; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPINAL CORD TUMOR; THORAX TUMOR; TREATMENT OUTCOME; VERTEBRA;

ANTIGENS, CD34; CHILD; DERMATOFIBROSARCOMA; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MAGNETIC RESONANCE IMAGING; ONCOGENE PROTEINS, FUSION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SPINAL NEOPLASMS; THORACIC NEOPLASMS; THORACIC VERTEBRAE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84870060348     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0b013e31826b7919     Document Type: Article

References (27)

1. Aiba S, Tabata N, Ishii H, et al. Dermatofibrosarcoma protuberans is a unique fibrohistiocytic tumour expressing CD34. Br J Dermatol. 1992;127:79-84.
2. Mentzel T, Beham A, Katenkamp D, et al. Fibrosarcomatous ("high-grade") dermatofibrosarcoma protuberans: clinicopathologic and immunohistochemical study of a series of 41 cases with emphasis on prognostic significance. Am J Surg Pathol. 1998;22:576-587.
3. Bowne WB, Antonescu CR, Leung DH, et al. Dermatofibrosarcoma protuberans: a clinicopathologic analysis of patients treated and followed at a single institution. Cancer. 2000;88:2711-2720.
4. Goldblum JR, Reith JD, Weiss SW. Sarcomas arising in dermatofi-brosarcoma protuberans: a reappraisal of biologic behavior in eighteen cases treated by wide local excision with extended clinical follow up. Am J Surg Pathol. 2000;24:1125-1130.
5. Sandberg AA, Bridge JA. Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors. Dermatofibro-sarcoma protuberans and giant cell fibroblastoma. Cancer Genet Cytogenet. 2003;140:1-12.
6. Pedeutour F, Simon MP, Minoletti F, et al. Translocation, t(17;22)(q22;q13), in dermatofibrosarcoma protuberans: a new tumor-associated chromosome rearrangement. Cytogenet Cell Genet. 1996;72:171-174.
7. Sirvent N, Maire G, Pedeutour F. Genetics of dermatofibrosarcoma protuberans family of tumors: from ring chromosomes to tyrosine kinase inhibitor treatment. Genes Chromosomes Cancer. 2003;37:1-19.
8. Wang J, Morimitsu Y, Okamoto S, et al. COL1A1-PDGFB fusion transcripts in fibrosarcomatous areas of six dermatofibrosarcomas protuberans. J Mol Diagn. 2000;2:47-52.
9. Kesserwan C, Sokolic R, Cowen EW, et al. Multicentric dermatofi-brosarcoma protuberans in patients with adenosine deaminase-deficient severe combined immune deficiency. J Allergy Clin Immunol. 2012;129:762-769.
10. Patel KU, Szabo SS, Hernandez VS, et al. Dermatofibrosarcoma protuberans COL1A1-PDGFB fusion is identified in virtually all dermatofibrosarcoma protuberans cases when investigated by newly developed multiplex reverse transcription polymerase chain reaction and fluorescence in situ hybridization assays. Hum Pathol. 2008; 39:184-193.
11. Weinstein JM, Drolet BA, Esterly NB, et al. Congenital dermatofi-brosarcoma protuberans: variability in presentation. Arch Dermatol. 2003;139:207-211.
12. Escalona-Zapata J, Alvarez Fernandez E, Llorca Escuin F. The fibroblastic nature of dermatofibrosarcoma protuberans. A tissue culture and ultrastructural study. Virchows Arch A Pathol Anat Histol. 1981;391:165-175.
13. Calonje E, Fletcher CD. Myoid differentiation in dermatofibrosar-coma protuberans and its fibrosarcomatous variant: clinicopatho-logic analysis of 5 cases. J Cutan Pathol. 1996;23:30-36.
14. Alguacil-Garcia A, Unni KK, Goellner Jr. Histogenesis of dermatofibrosarcoma protuberans. An ultrastructural study. Am J Clin Pathol. 1978;69:427-434.
15. Sellheyer K, Nelson P, Krahl D. Dermatofibrosarcoma protuber-ans: a tumour of nestin-positive cutaneous mesenchymal stem cells? Br J Dermatol. 2009;161:1317-1322.
16. O'Brien KP, Seroussi E, Dal Cin P, et al. Various regions within the alpha-helical domain of the COL1A1 gene are fused to the second exon of the PDGFB gene in dermatofibrosarcomas and giant-cell fibroblastomas. Genes Chromosomes Cancer. 1998;23:187-193.
17. Shimizu A, O'Brien KP, Sjoblom T, et al. The dermatofibrosarcoma protuberans-associated collagen type Ialpha1/platelet-derived growth factor (PDGF) B-chain fusion gene generates a transforming protein that is processed to functional PDGF-BB. Cancer Res. 1999;59:3719-3723.
18. Frierson HF, Cooper PH. Myxoid variant of dermatofibrosarcoma protuberans. Am J Surg Pathol. 1983;7:445-450.
19. Sanz-Trelles A, Ayala-Carbonero A, Rodrigo-Fernandez I, et al. Leiomyomatous nodules and bundles of vascular origin in the fibrosarcomatous variant of dermatofibrosarcoma protuberans. J Cutan Pathol. 1998;25:44-49.
20. O'Connell JX, Trotter MJ. Fibrosarcomatous dermatofibrosarcoma protuberans with myofibroblastic differentiaion: a histologically distinctive variant [corrected]. Mod Pathol. 1996;9:273-278.
21. Sigel JE, Bergfeld WF, Goldblum Jr. A morphologic study of dermatofibrosarcoma protuberans: expansion of a histologic profile. J Cutan Pathol. 2000;27:159-163.
22. Sheng WQ, Hashimoto H, Okamoto S, et al. Expression of COL1A1-PDGFB fusion transcripts in superficial adult fibrosarco-ma suggests a close relationship to dermatofibrosarcoma protuber-ans. J Pathol. 2001;194:88-94.
23. Ratner D, Thomas CO, Johnson TM, et al. Mohs micrographic surgery for the treatment of dermatofibrosarcoma protuberans. Results of a multiinstitutional series with an analysis of the extent of microscopic spread. J Am Acad Dermatol. 1997;37:600-613.
24. Suit H, Spiro I, Mankin HJ, et al. Radiation in management of patients with dermatofibrosarcoma protuberans. J Clin Oncol. 1996; 14:2365-2369.
25. Lemm D, Mugge LO, Mentzel T, et al. Current treatment options in dermatofibrosarcoma protuberans. J Cancer Res Clin Oncol. 2009; 135:653-665.
26. Rutkowski P, Van Glabbeke M, Rankin CJ, et al. Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials. J Clin Oncol. 2010;28:1772-1779.
27. Gooskens SL, Oranje AP, van Adrichem LN, et al. Imatinib mesylate for children with dermatofibrosarcoma protuberans (DFSP). Pediatr Blood Cancer. 2010;55:369-373.